Exozymes Inc (EXOZ)

$EXOZ NCT as a supportive supplement to GLP-1s In a pivotal mouse study, NCT given alongside a high-fat diet led to 35-40% less weight gain compared to mice just on a high-fat diet. On its own, NCT doesn't cause rapid weight loss. In another study, obese mice given NCT for 2 weeks saw no drop in body weight however, it did reverse their fatty livers. This suggests NCT may help people maintain normal eating patterns without putting on as much weight. For those already obese, GLP-1s could be used for rapid initial weight loss and then NCT could be taken afterwards for maintenance and weight gain prevention. NCT keeps metabolism rates high, effectively fighting the body's natural tendency to slow down metabolism and regain weight. It also helps reverse obesity-related mitochondrial and liver damage. Importantly, it promotes lipophagy, where liver cells break down their own stored fat. A clearer, healthier liver directs incoming calories toward energy production instead of fat storage.

$EXOZ Great to see new investors following the company! Just a reminder that we've set up an eXoZymes Investor Discord

In a recent LA Weekly article, eXoZymes (Nasdaq: $EXOZ ) discussed its AI-driven approach to biomanufacturing rare cannabinoids and nutraceuticals. eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. The article explores why traditional extraction methods fall short for ultra-rare bioactive compounds: they require massive amounts of plant material to yield tiny quantities, making commercial production impractical. To solve this problem, eXoZymes uses AI to engineer enzymes (the proteins that catalyze chemical reactions in living things) to work outside of cells in industrial bioreactors. This “cell-free” approach allows them to manufacture compounds that would otherwise be inaccessible, including non-psychoactive cannabinoids with therapeutic potential. Cannabinoid Program Director John Billingsley noted, “Our new BioClick approach opens the door to the biomanufacturing of rare and previously unthinkable target molecules that can be game-changers in medicine, nutrition, and other functional nutraceuticals.” The company recently demonstrated the platform’s potential by producing gram-scale quantities of NCT, a metabolism-boosting compound, at over 99% purity in just five months. Read the article here: https://www.laweekly.com/the-enzyme-frontier-exozymes-unlocks-a-new-era-for-cannabinoid-nutraceuticals-and-pharma/ eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

A newly-released video from eXoZymes (Nasdaq: $EXOZ ) offers a compelling look at how the company is using AI-driven enzyme engineering to expand the potential of NCT. eXoZymes is a B2i Digital Featured Company. See the full profile at https://b2idigital.com/exozymes-1. As Michael Heltzen, CEO of eXoZymes, explains in the interview, GLP-1 drugs reduce appetite while NCT supports metabolism in a different way. He notes that NCT has been part of the human diet for a long time, although meaningful doses were historically difficult to achieve. Their platform allows NCT to be produced at scale, which creates opportunities for both an over-the-counter supplement and future pharmaceutical applications. Heltzen also describes how eXoZymes applies AI to design enhanced enzyme variants that enable the creation of new molecules and new classes of chemistry. Watch the complete interview at: https://exozymes.com/blog/upside-interview-episode2 eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ recent Q3 investor call was, in my view, a genuine inflection point for the company. I’ve just published a new Substack breaking down 7 key takeaways that have made me even more bullish on $EXOZ https://www.slack-capital.com/p/exozymes-q3-investor-call

In a recent video update, eXoZymes Inc. (NASDAQ: $EXOZ ) CEO Michael Heltzen shared insights from his visit to NASDAQ headquarters in New York. eXoZymes Inc is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. CEO Heltzen discusses his productive time in New York, where media engagements included interviews for both written and recorded outlets, with a segment scheduled to appear on the NASDAQ News Channel. Beyond media activities, he connected with new investor audiences at conferences where eXoZymes was specifically invited to introduce its platform. Most notably, Heltzen joined pharmaceutical companies and industry leaders on a panel to showcase how eXoZymes distinctively leverages AI—generating substantial data to identify which mutations create better enzymes and molecules while optimizing reinforcement training loops for tangible ROI. Heltzen commented: “People are very intrigued about what we are building overall, but specifically NCTx as a business opportunity is something that is really fascinating people, and we are getting a lot of really good interactions on that as we are starting to get recognized as super users of AI in the pharmaceutical industry.” Watch the full CEO update: https://youtu.be/cWP8MeDnMlo eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased and currently owns shares of unrestricted VYCO stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of VYCO or any security, nor is it intended to offer any opinion on VYCO as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

$EXOZ 🚀 The Upside Episode #2 is live! AI changed how we process data. And eXoZymes is using AI-created enzymes to change how we process matter. This is biomanufacturing without cells – faster, cleaner, smarter. My conversation with CEO Michael Heltzen is live. No spin. Just pure, programmable biology – and the upside behind it. 👉 Watch the full interview: https://tbsupside.com/exoz/

eXoZymes (Nasdaq: $EXOZ ) announced the appointment of co-founder Tyler Korman, PhD as Chief Scientific Officer and Amy Lunzer as Chief of Staff. eXoZymes Inc is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. Dr. Korman, whose career in biomanufacturing began over 20 years ago and who founded Invizyne (which became eXoZymes) has progressed through multiple leadership roles including Director of R&D and VP of Research before assuming the CSO position. With his extensive background in cell-free biomanufacturing, he will lead R&D strategy for the company’s proprietary exozyme platform and drive the development of biosolutions that transform sustainable feedstock into high-value molecules. Amy Lunzer joins as Chief of Staff, bringing her expertise as an accomplished business, supply chain, and operations executive to strengthen the company’s operational capabilities as it advances its technology platform toward commercial applications. CSO Tyler Korman stated: “I’m excited to announce that I’m now the Chief Scientific Officer! This journey started over 20 years ago including founding Invizyne, which then became eXoZymes. I’m grateful to have held roles as Director of R&D to VP of Research and now CSO - where I can really push through our strategy for how we become the leader in biomanufacturing.” He added: “In my opinion, we stand at a crossroads where we need new solutions to be able to produce important molecules for use as nutraceuticals and pharmaceuticals - and I think we have those solutions. That makes me excited about the future of biomanufacturing!” See the full news release at: https://exozymes.com/blog/tyleramy eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted HMR stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of HMR or any security, and it is not intended to offer any opinion on HMR as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

eXoZymes (Nasdaq: EXOZ) Inc. (NASDAQ: $EXOZ ) announced its Q3 operational update for the fiscal quarter ended October 31, 2025. eXoZymes Inc is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. During the quarter, eXoZymes continued to advance multiple development and commercialization pathways across its platform. The company highlighted progress within its purpose-built NCTx subsidiary, ongoing development of its santalene biosolution for sustainable fragrance production, and continued work on its non-intoxicating cannabinoid program. The company also noted organizational expansion and strengthened capabilities across R&D, operations, and scientific leadership. Notable developments during the quarter included: • NCTx advanced its exploratory analog program, which remains contingent on further development, validation, regulatory processes, and commercialization outcomes • Continued parallel development of santalene and non-intoxicating cannabinoid assets • Expanded R&D capabilities and leadership team to accelerate product development • The company ended Q2 2025 with $5.1 million in cash and cash equivalents, supporting operations into the beginning of Q2 2026 • Appointment of Amy Lunzer as Chief of Staff and Dr. Tyler Korman, co-founder of eXoZymes and cell-free biomanufacturing specialist, as Chief Scientific Officer CEO Michael Heltzen commented: “Since our last quarterly update, we have worked diligently on maturing our core assets – both scientifically as well as commercially – including what the ideal go-to-market strategies are for each of these. We look forward to sharing these details with our investors on the call today.” See the full news release at: https://exozymes.com/blog/2025-3q-update eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.

$EXOZ One of @eXoZymes assumed risks is scaling production... Yet the company recently disclosed its platform can already synthesise compounds at KILOGRAM-SCALE THIS IS MASSIVE. Many of their initial targets in nutraceuticals ($500-5,000/kg) and pharmaceuticals ($5,000-500,000/kg) require only kilogram quantities ANNUALLY This means eXoZymes is already at commericalcommercial-ready-ready state, de-risking early revenue timing and partnership ramp-up These fundamentals (high-value compounds, scaled production, low-cost) are what create a real 100x investment opportunity